Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumor

Interventions

DRUG: TNG462
DRUG: Pembrolizumab

Sponsor

Tango Therapeutics, Inc.